

**CGS Administrators**

**Jurisdiction 15**

**Carrier Advisory Committee Meeting**

October 19, 2015  
October 20, 2015

---

**Carrier Advisory Committee Meeting**

**Agenda**

- Introductions
- Co-Chair Remarks
- CMD Comments
- Comprehensive Error Rate Testing (CERT) Update
- CGS Medical Review (MR)
- Provider Outreach & Education (POE)
- Local Coverage Determinations (LCDs)
- Closing Comments

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC

**Carrier Advisory Committee Meeting**

## CMD Comments

- J-15 Contract Award
- Upcoming CAC rotation
- Prepay reviews
- MoIDx JOA
- ICD-10

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC


**Carrier Advisory Committee Meeting**

## CERT Update

### Part A – Top Errors

Category	May	June	July	Aug	Sept
Admit / 2 Midnight	23.01%	23.60%	48.19%	41.63%	18.06%
DRG	6.44%	1.68%	10.90%	4.28%	8.12%
IRF	0.00%	26.55%	3.44%	59.23%	11.05%
Coding	0.00%	0.00%	0.00%	0.00%	11.05%

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC



- Carrier Advisory Committee Meeting**
- ## CGS Medical Review (MR)
- As part of the Part B Medical Review Strategy, MR is currently focusing on specific probes. Top findings for current reviews:
    - Emergency Room Visits: Overall provider error rate = 48.73%
      - Failure to meet key component levels
        - <http://cgsmedicare.com/partb/pubs/news/2012/0512/cope18822.html>
      - Failure to meet guidelines for split/shared visits
        - <http://www.cgsmedicare.com/partb/pubs/news/2013/1113/cope23908.html>
      - Failure to meet signature guidelines
        - <http://www.cgsmedicare.com/partb/pubs/news/2014/0214/cope24803.html>

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC

## CGS Medical Review (MR)

- As part of the Part B Medical Review Strategy, MR is currently focusing on specific probes. Top findings for current reviews (*cont*):
  - Hospital Visits: Overall provider error rate = 66.51%
    - Failure to meet key component levels
    - Medically unnecessary services, including frequency
      - <http://www.cgsmedicare.com/partb/cert/articles/045.html>
    - Inappropriate documentation for split/shard services
- Review the *Part B Medical Review Activity Log* for a listing of active and pending reviews
  - [http://www.cgsmedicare.com/partb/mr/activity\\_log.html](http://www.cgsmedicare.com/partb/mr/activity_log.html)

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC

## CGS Medical Review (MR)

- As part of Medical Review's focus for the upcoming Option Year, the following items will be reviewed as part of our Strategy
  - Evaluation & Management Codes
  - Labs
  - Ambulance
  - Drugs
  - Chiropractic
  - Other items will be reviewed based on data analysis and other reports as necessary

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC

## Provider Outreach & Education

- *Medicare In The News*
- Calendar of Events
  - Part A: [http://cgsmedicare.com/medicare\\_dynamic/wrkshp/pr/parta\\_report.asp](http://cgsmedicare.com/medicare_dynamic/wrkshp/pr/parta_report.asp)
  - Part B: [http://cgsmedicare.com/medicare\\_dynamic/wrkshp/pr/partb\\_report.asp](http://cgsmedicare.com/medicare_dynamic/wrkshp/pr/partb_report.asp)
  - HHH: <http://cgsmedicare.com/hhh/education/education.html>
- To request a meeting with the provider outreach staff
  - Send email request to [J15\\_PartB\\_Education@cgsadmin.com](mailto:J15_PartB_Education@cgsadmin.com)

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC

## Local Coverage Determinations (LCDs)

- New Policies
 

Policies are effective **October 1, 2015**

  - L35984: MoPath: Genetic Testing for Hypercoagulability / Thrombophilia (Factor V Leiden, Factor II Prothrombin, and MTHFR)
  - L36021: Molecular Diagnostic Tests (MDTs)-several articles attached
  - L36174: MoPath: NSCLC, Comprehensive Genomic Profile Testing
  - L35986: MoPath: Special Histochemical Stains and Immunohistochemical Stains

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC  
CPT only copyright 2015 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DARS Restrictions Apply to Government Use.

## Local Coverage Determinations (LCDs)

- New Policies (*con't*)

Policies are effective **October 5, 2015**

- L36029: Controlled Substance Monitoring and Drugs of Abuse Testing
- L36139: MoPath: Biomarkers in Cardiovascular Risk Assessment
- L36115: MoPath: BRCA1 and BRCA2 Genetic Testing
- L36127: MoPath: Breast Cancer Assay: Prosigna
- L36004: MoPath: Breast Cancer Index &#8480 Genetic Assay
- L36006: MoPath: ConfirmMDx Epigenetic Molecular Assay
- L36009: MoPath: Decipher® Prostate Cancer Classifier Assay

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC  
CPT only copyright 2015 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARSDFARS Restrictions Apply to Government Use.

## Local Coverage Determinations (LCDs)

- New Policies (*con't*)

Policies are effective **October 5, 2015**

- L36117: MoPath: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease
- L36206: MoPath: Genomic Health™ Oncotype DX® Prostate Cancer Assay
- L36048: MoPath: HLA-B\*15:02 Genetic Testing
- L36113: MoPath: MGMT Promoter Methylation Analysis
- L36011: MoPath: Molecular RBC Phenotyping
- L36002: Mopath: Prolaris™ Prostate Cancer Genomic Assay

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC  
CPT only copyright 2015 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARSDFARS Restrictions Apply to Government Use.

## Local Coverage Determinations (LCDs)

### ■ Revised Policies

All LCDs that had the name MoPath were changed to MoIDx with CGS teaming with the MoIDx team concerning molecular pathology.

- L34053: Application of Cellular and/or Tissue Based Products (CTPs) for Wounds of Lower Extremities
  - Added HCPCS code Q4117 as covered
- L34093: Chemotherapy and Biologicals
  - Added FDA approved ICD-10 codes for osteoporosis for Denosumab
  - Added new drug Carfilzomab (HCPCS code J9047)
  - Added new ICD-10 codes for HCPCS codes J9000, J9181, J9045, and J9263

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC

CPT only copyright 2015 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARSDFARS Restrictions Apply to Government Use.

## Local Coverage Determinations (LCDs)

### ■ Revised Policies (*con't*)

- L34175: Ophthalmic Angiography (Fluorescein and Indocyanine Green)
  - ICD-10 groups 3 and 4 removed; added in error since the secondary dx in stand alone group added ICD-10 codes E10.65 and E11.65 to group 1
- L34062: Dialysis Access Maintenance
  - Added paragraph at end of limitations section concerning stage procedure for fistula
- L34200: Removal Benign Skin lesions
  - Added ICD-10 codes L72.11 and L72.12

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC

CPT only copyright 2015 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARSDFARS Restrictions Apply to Government Use.

## Local Coverage Determinations (LCDs)

- Draft Policies
  - DL36425: MoIDX: Breast Cancer Assay: Prosigna (Policy back in draft because ICD-10 codes related to male breast cancer has been removed)
  - DL36456: MoIDX: BRCA1 and BRCA2 Genetic Testing (Policy back in draft due to removal of ICD-10 codes for carcinoma in situ and addition of several other new ICD-10 codes)
  - DL36458: MoIDX: Breast Cancer Index<sup>SM</sup> Genetic Assay (Policy back in draft due to several changes made to the policy)
  - DL36460: Bone Mass Measurement

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC

CPT only copyright 2015 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARSDFARS Restrictions Apply to Government Use.

## Local Coverage Determinations (LCDs)

- Draft Policies (*con't*)
  - DL36469: Repetitive Transcranial Magnetic Stimulation (rTMS) in Adults with Treatment Resistant Major Depressive Disorder
  - DL36485: MoIDX: HLA-DQB1\*06:02 Testing for Narcolepsy
  - DL36487: MoIDX: Chromosome 1p/19q deletion analysis
  - DL36494: Minimally-invasive Surgical (MIS) Fusion of the Sacroiliac (SI) Joint

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC

CPT only copyright 2015 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARSDFARS Restrictions Apply to Government Use.



## Contact Us!

- To ensure inquiries are tracked and widespread issues are properly evaluated:
  - J15 Part A Provider Customer Service
    - 866.590.6703 – Monday through Friday, 8:00 a.m. – 5:00 p.m. ET
  - J15 Part B Provider Customer Service
    - 866.276.9558 – Monday through Friday, 8:00 a.m. – 5:00 p.m. ET
  - J15 Home Health & Hospice Customer Service
    - 877.299.4500 – Monday through Friday, 8:00 a.m. – 4:30 p.m. CT
- For issues related to medical policy
  - Contact the CMDs at [CMD.Inquiry@cgsadmin.com](mailto:CMD.Inquiry@cgsadmin.com)
    - This will ensure the request is handled even when the CMDs are out of the office.

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC

## Future CAC Dates

- **Kentucky and Ohio**
  - February 2016 (date TBD)
    - Teleconference
  - June 2016 (date TBD)
    - Joint meeting – location TBD
- All meetings will begin at 6:00 p.m. ET
- All dates are tentative

Revised October 7, 2015  
© 2015 Copyright, CGS Administrators, LLC